News MERUS LABS INTERNATIONAL INC (U-MSLI) - News Release
Merus Labs Provides an Update on German Reimbursement Review
2015-06-03 16:00 ET - News Release
TORONTO, June 3, 2015 /PRNewswire/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI], is providing an update on the review of the German Federal Joint Committee (the "G-BA") related to Emselex® (Darifenacin).
Last summer, the Company was informed by the G-BA of a plan to introduce a reimbursement class for anticholinergic-based overactive bladder products for the publicly-funded market in Germany. The Company provided a written submission to the G-BA in August 2014 which set out the Company's case for Emselex®'s superior side-effect profile and improved patient compliance when compared to older, lower priced products in the same category.
A hearing is now scheduled for June 9th, which is an expected part of the detailed G-BA evaluation process. A number of pharmaceutical companies and other stakeholders will attend. Merus Labs will be represented by Mr. Frank Rotmann, the Company's VP & Head of European Operations.
Future updates will be provided as new material information becomes available. The Company anticipates that a final determination of a possible maximum reimbursement price and the specific products which will be included in the proposed class, will likely not occur during the Company's current fiscal year.